The 5-year analysis had shown that a short , albeit intensive , postoperative course of antibody treatment (900 mg total dose)significantly reduced the appearance of distant metastases , but did not affect the rate of local relapses .
For the immediate future , adding antibody to chemotherapy seems logical to attack both dormant , as well as proliferating, metastatic tumor cells .
